Crinetics Pharmaceuticals Inc (CRNX)
51.31
-0.60
(-1.16%)
USD |
NASDAQ |
May 20, 12:52
Crinetics Pharmaceuticals Net Income (Quarterly): -66.93M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -66.93M |
December 31, 2023 | -60.10M |
September 30, 2023 | -57.46M |
June 30, 2023 | -50.98M |
March 31, 2023 | -46.00M |
December 31, 2022 | -44.99M |
September 30, 2022 | -41.92M |
June 30, 2022 | -42.38M |
March 31, 2022 | -34.63M |
December 31, 2021 | -30.79M |
September 30, 2021 | -27.85M |
June 30, 2021 | -26.10M |
March 31, 2021 | -22.90M |
December 31, 2020 | -21.64M |
September 30, 2020 | -18.32M |
Date | Value |
---|---|
June 30, 2020 | -16.49M |
March 31, 2020 | -17.36M |
December 31, 2019 | -14.55M |
September 30, 2019 | -14.43M |
June 30, 2019 | -12.43M |
March 31, 2019 | -9.016M |
December 31, 2018 | -8.495M |
September 30, 2018 | -7.588M |
June 30, 2018 | -5.568M |
March 31, 2018 | -5.464M |
December 31, 2017 | -2.521M |
September 30, 2017 | -2.382M |
June 30, 2017 | -1.648M |
March 31, 2017 | -2.606M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-66.93M
Minimum
Mar 2024
-12.43M
Maximum
Jun 2019
-33.41M
Average
-29.32M
Median
Net Income (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 23.28M |
Geron Corp | -55.39M |
Madrigal Pharmaceuticals Inc | -147.54M |
PTC Therapeutics Inc | -91.58M |
Syndax Pharmaceuticals Inc | -72.40M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 0.64M |
Total Expenses (Quarterly) | 74.17M |
EPS Diluted (Quarterly) | -0.93 |
Enterprise Value | 3.152B |
Profit Margin (Quarterly) | -10.46K% |
Earnings Yield | -7.37% |
Normalized Earnings Yield | -7.367 |